A sentiment survey tied to the aftermath of FDA leadership changes reports the regulatory environment is improving in biotech sentiment, though other areas remain mixed. Endpoints Signal’s Q3 Biopharma Sentiment Index reported regulation as the only domain where pessimists still slightly outnumber optimists earlier, with optimism rising after departures including FDA commissioner Marty Makary and biologics chief Vinay Prasad.